<DOC>
	<DOC>NCT00838383</DOC>
	<brief_summary>This is a multi-center, randomized study of sitaxsentan administered intravenously to subjects who are undergoing elective CABG, cardiac valve replacement, or combined CABG and cardiac valve replacement procedures that require CPB.</brief_summary>
	<brief_title>Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery</brief_title>
	<detailed_description />
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Has been identified for coronary artery bypass grafting (CABG), aortic and/or mitral valve replacement, or combined CABG and cardiac valve replacement procedures that require cardiopulmonary bypass (CPB). Requires an emergent or "emergency" CABG and/or cardiac valve replacement.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>multi-center, placebo-controlled, randomized study of sitaxsentan administered to subjects post-cross-clamp release and 12 hours post-CPB</keyword>
</DOC>